CHO-K1/Rat D3 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0084C | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The dopamine D3 receptor is a member of the D2-like receptor subfamily and exhibits the highest affinity for dopamine among all dopamine receptors. Its distribution is notably restricted to the limbic system, with the highest density in the nucleus accumbens and olfactory tubercle, areas critical for emotion and reward. Functionally, the D3 receptor primarily modulates motivation, reward, cognition, and emotional processes and plays a central role in the reinforcing effects and drug-seeking behaviors of addiction. It is also implicated in the negative symptoms of schizophrenia (e.g., anhedonia, social withdrawal) and impulse control disorders associated with Parkinson's disease therapy. Consequently, selective D3 receptor ligands (e.g., partial agonists) are a major focus for developing new-generation antipsychotic and anti-addiction medications.
Screeningbio’s CHO-K1/Rat D3 cell line overexpress DRD3 and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Rat |
HGNC Symbol | DRD3 |
Accession Number | NM_017140 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The dopamine D3 receptor is a member of the D2-like receptor subfamily and exhibits the highest affinity for dopamine among all dopamine receptors. Its distribution is notably restricted to the limbic system, with the highest density in the nucleus accumbens and olfactory tubercle, areas critical for emotion and reward.
Functionally, the D3 receptor primarily modulates motivation, reward, cognition, and emotional processes and plays a central role in the reinforcing effects and drug-seeking behaviors of addiction. It is also implicated in the negative symptoms of schizophrenia (e.g., anhedonia, social withdrawal) and impulse control disorders associated with Parkinson's disease therapy.
Consequently, selective D3 receptor ligands (e.g., partial agonists) are a major focus for developing new-generation antipsychotic and anti-addiction medications.